Cargando…

Pneumothorax in patients with idiopathic pulmonary fibrosis: a real-world experience

BACKGROUND: Some patients with idiopathic pulmonary fibrosis (IPF) develop pneumothorax. However, the characteristics of pneumothorax in patients with IPF have not been elucidated. The purpose of this study was to clarify the clinical course, actual management, and treatment outcomes of pneumothorax...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamazaki, Ryo, Nishiyama, Osamu, Gose, Kyuya, Saeki, Sho, Sano, Hiroyuki, Iwanaga, Takashi, Tohda, Yuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789641/ https://www.ncbi.nlm.nih.gov/pubmed/33407311 http://dx.doi.org/10.1186/s12890-020-01370-w

Ejemplares similares

Comparison of CURB-65, PSI, and qSOFA for predicting pneumonia mortality in patients with idiopathic pulmonary fibrosis
por: Yamazaki, Ryo, et al.
Publicado: (2021)

Characteristics of patients with chronic idiopathic interstitial pneumonia undergoing repeated respiratory-related hospitalizations: A retrospective cohort study
por: Yamazaki, Ryo, et al.
Publicado: (2020)

The utility of the Japanese Association for Acute Medicine DIC scoring system for predicting survival in acute exacerbation of fibrosing idiopathic interstitial pneumonia
por: Yamazaki, Ryo, et al.
Publicado: (2019)

Initial therapeutic dose of corticosteroid for an acute exacerbation of IPF is associated with subsequent early recurrence of another exacerbation
por: Yamazaki, Ryo, et al.
Publicado: (2021)

HFpEF without elevated right ventricular systolic pressure is a favorable prognostic indicator in patients with IPF requiring hospitalization for heart failure
por: Yamazaki, Ryo, et al.
Publicado: (2021)

Pulmonary Hemodynamics and Six-Minute Walk Test Outcomes in Patients with Interstitial Lung Disease
por: Nishiyama, Osamu, et al.
Publicado: (2016)

Clinical Features and Outcomes of IPF Patients Hospitalized for Pulmonary Infection: A Japanese Cohort Study
por: Yamazaki, Ryo, et al.
Publicado: (2016)

The phosphodiesterase 4 inhibitor AA6216 suppresses activity of fibrosis-specific macrophages
por: Matsuhira, Takashi, et al.
Publicado: (2021)

Which inhaled corticosteroid and long-acting β-agonist combination is better in patients with moderate-to-severe asthma, a dry powder inhaler or a pressurized metered-dose inhaler?
por: Muraki, Masato, et al.
Publicado: (2017)

The current state and provisions for elderly patients with asthma
por: Iwanaga, Takashi, et al.
Publicado: (2017)

A scoring algorithm for predicting the presence of adult asthma: a prospective derivation study
por: Tomita, Katsuyuki, et al.
Publicado: (2013)

Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
por: Nishiyama, Osamu, et al.
Publicado: (2021)

Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
por: Tzouvelekis, Argyrios, et al.
Publicado: (2017)

Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis
por: Nishiyama, Osamu, et al.
Publicado: (2021)

Corrigendum: Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
por: Tzouvelekis, Argyrios, et al.
Publicado: (2018)

4569 Burden of illness in idiopathic pulmonary fibrosis: A real-world cohort
por: Farrand, Erica, et al.
Publicado: (2020)

Medication persistence rates and predictive factors for discontinuation of antifibrotic agents in patients with idiopathic pulmonary fibrosis: a real-world observational study
por: Oishi, Keiji, et al.
Publicado: (2019)

Depression Is Significantly Associated with the Health Status in Patients with Idiopathic Pulmonary Fibrosis
por: Matsuda, Toshiaki, et al.
Publicado: (2017)

Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience
por: Rivera-Ortega, Pilar, et al.
Publicado: (2018)

Occurrence of Idiopathic Pulmonary Fibrosis in Italy: Latest Evidence from Real-World Data
por: Iommi, Marica, et al.
Publicado: (2022)

Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent, et al.
Publicado: (2015)

Real world experience on the effectiveness and safety of pirfenidone in patients with idiopathic pulmonary fibrosis in Taiwan
por: Chang, Cheng-Yu, et al.
Publicado: (2023)

Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and COPD: A Propensity-Matched Real-World Study
por: Nolan, Claire M., et al.
Publicado: (2022)

The Respimat(®) Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients
por: Iwanaga, Takashi, et al.
Publicado: (2019)

Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis
por: Hughes, Gareth, et al.
Publicado: (2016)

Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis
por: Wright, William Alexander, et al.
Publicado: (2021)

A Narrative Review of Real-World Data on the Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
por: Podolanczuk, Anna J., et al.
Publicado: (2023)

Real-world practice of idiopathic pulmonary fibrosis: Results from a 2000–2016 cohort
por: Wang, Ying-Tso, et al.
Publicado: (2023)

Diaphragm dome height on chest radiography as a predictor of dynamic lung hyperinflation in COPD
por: Shiraishi, Masashi, et al.
Publicado: (2023)

Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan
por: Ogura, Takashi, et al.
Publicado: (2023)

A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis
por: Dhooria, Sahajal, et al.
Publicado: (2020)

Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
por: Wuyts, Wim A., et al.
Publicado: (2019)

Involvement of Allosteric Effect and K(Ca) Channels in Crosstalk between β(2)-Adrenergic and Muscarinic M(2) Receptors in Airway Smooth Muscle
por: Kume, Hiroaki, et al.
Publicado: (2018)

The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study
por: Cameli, Paolo, et al.
Publicado: (2022)

Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: a two centre retrospective study
por: Eaden, James A., et al.
Publicado: (2020)

Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
por: Wencel, Mark L., et al.
Publicado: (2018)

The efficacy of nintedanib in 158 patients with idiopathic pulmonary fibrosis in real-world settings: A multicenter retrospective study
por: Dobashi, Masaki, et al.
Publicado: (2021)

Economic Burden of Idiopathic Pulmonary Fibrosis in Spain: A Prospective Real-World Data Study (OASIS Study)
por: Rodríguez-Nieto, Maria Jesus, et al.
Publicado: (2023)

A Real-World Prognosis in Idiopathic Pulmonary Fibrosis: A Special Reference to the Role of Antifibrotic Agents for the Elderly
por: Honda, Kojiro, et al.
Publicado: (2023)

Clinical Profile of Patients with Idiopathic Pulmonary Fibrosis in Real Life
por: Morena, Diego, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nkldkafdd4jfbs9ticqvuk1f0b